Boston Scientific stock: Zacks trims EPS outlook as growth stalls

Published on 11/13/2026 at 16:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock faces a weaker growth outlook after Zacks cut its consensus EPS estimates for 2026 and 2027. Valuation remains in focus.

Growth expectations move lower

Zacks' consensus EPS estimate for 2026 fell to 3.17 US dollars from 3.29 over two months.
The 2027 consensus estimate declined to 3.09 US dollars from 3.39, leaving expected growth close to flat.
The analysis keeps Boston Scientific's valuation and franchise execution in focus after weaker growth expectations.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific faces a weaker earnings-growth setup after Zacks reduced its consensus EPS estimates for both 2026 and 2027. The assessment was published by Finviz on Friday, November 13, 2026, in a market analysis by Kevin Cook.

Estimates reset for 2027

The Zacks consensus EPS estimate for 2026 declined to 3.17 US dollars from 3.29 over the past two months, according to the analysis. The estimate for 2027 fell to 3.09 US dollars from 3.39, reducing the expected growth profile to roughly flat.

Finviz also described Boston Scientific as trading at about 15 times earnings and more than three times sales. That combination leaves valuation sensitive to further changes in revenue and profit expectations, even as the company continues to expand its medical-device business.

Franchise execution remains central

The analysis links the reset to Boston Scientific's third-quarter results and the weaker outlook discussed after the October 28 report. Investors are likely to focus on whether growth in the company's cardiovascular and surgical franchises can offset pressure in areas where recent coverage has highlighted slower momentum.

Boston Scientific stock traded at 40.19 euros on Lang & Schwarz at 16:02 CET on Friday, November 13, 2026.